TEL AVIV, ISRAEL--(Marketwired - Aug 7, 2017) - InspireMD, Inc. (NYSE American: NSPR) (NYSE MKT: NSPR) (NYSE American: NSPR.WS) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the publication of the independent study entitled, "One swallow does not a summer make but many swallows do: accumulating clinical evidence for nearly-eliminated peri-procedural and 30-day complications with mesh-covered stents, transforms the carotid revascularization field," in the Advances in Interventional Cardiology Journal 2017.

The paper illustrates that carotid artery stenting (CAS) has the potential to be an equally safe, but less invasive, alternative to the surgical carotid endarterectomy (CEA) procedure. A link to the full article is available on the InspireMD website.

The paper was co-authored by Dr. Piotr Musiałek, Department of Cardiac and Vascular Diseases, Jagiellonian University, School of Medicine, John Paul II Hospital, Krakow, Poland, Professor L. Nelson Hopkins and Professor Adnan H. Siddiqui, both of the Departments of Neurosurgery and Radiology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Jacobs Institute, Gates Vascular Institute Kaleida Health, Buffalo, New York, USA.
The review finds that data from more than 550 patients in mesh-covered and dual layered carotid device clinical studies show an overall 30-day complication rate of ~1% with near-elimination of post-procedural events. This data, combined with other historical data on patients with symptomatic and asymptomatic carotid stenosis confirming no difference between CAS and CEA long term stroke risk, serve to illustrate the potential transformation of the carotid revascularization field.

Additional highlights from the paper include:
CGuard™ EPS' open cell stent design together with SmartFit technology provides superior conformability compared to other next generation carotid devices, even in torturous lesions;
MicroNet covering has a very small pore size, thus provides maximum protection from protruding plaque;
CGuard™ EPS has a better radial force than current alternatives, and this, together with the open stent design, allows it to conform effectively to the vessel wall;
Current alternatives have no known tapered version of their stent, so unlike CGuard™ EPS, the operator needs to make measurements and calculations to ensure proper coverage of the lesion as there is considerable foreshortening.

Cardiology Homepage